tirzepatide trial sign up for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled SURPASS to SURMOUNT: The Tirzepatide

Research published in JCI Insight (Willard et al., 2020) describes tirzepatide as an imbalanced and biased dual agonist showing greater receptor occupancy at the GIPR than at the GLP-1R under clinically relevant concentrations

Why Choose Herglowlabs Bacteriostatic Water High-quality sterile multi-dose vials Optimal benzyl alcohol concentration Reliable Australian-sourced components Fast & discreet shipping AU Owned & Operated Disclaimer: This Bacteriostatic Water is intended strictly for qualified laboratory research use only to reconstitute peptides

Only 1 in 10 Patients Told to Lose Weight Seek Help From a Health Professional: A Nationally Representative Sample

Tirzepatide is a GIP and GLP-1 receptor agonist, working in similar ways to Semaglutide but with the added benefit of GIP, which may further improve the regulation of food intake and blood sugar levels

Oral users see more variation between doses because the within-subject variability in bioavailability is roughly 137% for individual doses